Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omnitrope 3.3 mg/mL in pre-pubertal children with growth hormone deficiency
2015-002802-34Phase 3
- Sponsor
- Sandoz
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in growth hormone deficiency (GHD), sponsored by Sandoz. Primary endpoint: Increase in growth rate over 12 months.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2015-002802-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002802-34.